Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

Bidard, François-Clément; Mathiot, Claire; Delaloge, Suzette; Brain, Étienne; Giachetti, S.; Crémoux, Patricia de; Marty, M.; Pierga, Jean‐Yves

doi:10.1093/annonc/mdp391

Cited by 227 publications

(151 citation statements)

References 10 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Micrometastases as well as the number of circulating tumor cells are associated with the incidence of distant metastases as well as with the overall survival of breast cancer patients [122][123][124]. For patient's prognosis, these parameters of tumor spread could be more relevant than the likelihood of a metastasis from lymph nodes [125,126].…”

Section: Do Lymph Node Metastases Metastasize?mentioning

confidence: 99%

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Gerber

Heintze

Stubert

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Evaluation of axillary lymph node status by sentinel lymph node biopsy (SLNB) and complete axillary lymph node dissection (ALND) are an inherent part of breast cancer treatment. Increased understanding of tumor biology has changed the prognostic and therapeutic impact of lymph node status. Non-invasive imaging techniques like axillary ultrasound, FDG-PET or MRI revealed moderate sensitivity and high specificity in evaluation of lymph node status. Therefore, they are not sufficient for lymph node staging. Otherwise the impact of remaining micrometastases and even macrometastases for prognosis and treatment decisions is overestimated.Considering tumor biology, the distinction of axillary metastases in isolated tumor cells (ITC, pN0[i+]); micrometastases (pN1mi), and macrometastases (pN1a)

show abstract

Section: Do Lymph Node Metastases Metastasize?mentioning

confidence: 99%

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Gerber

Heintze

Stubert

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Although 70% of patients with metastatic breast cancer (mBC) have !1 CTC/7.5 mL of blood, in primary breast cancer (pBC), this proportion is only as low as 20% to 25% (1)(2)(3)(4)(5)(6). In both cases, the presence of CTCs is associated with poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

Onstenk

Kraan

Mostert

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Circulating tumor cells (CTC) are detected by the CellSearch System in 20% to 25% of patients with primary breast cancer (pBC). To improve CTC detection, we investigated melanoma cell adhesion molecule (MCAM) as enrichment marker next to epithelial cell adhesion molecule (EpCAM) and tested the clinical relevance of MCAM-positive CTCs in patients with HER2-negative stage II/III pBC starting neoadjuvant chemotherapy (NAC) in the NEOZOTAC trial. Using the CellSearch System, EpCAM-positive and MCAM-positive CTCs were separately enriched from 7.5 mL blood, at baseline and after the first NAC cycle. Circulating endothelial cells (CEC) were measured using flow cytometry. Primary objective was to improve the CTC detection rate to !40% combining EpCAM/MCAM. Correlations of CTC and CEC counts and pathologic complete response (pCR) were also explored. At baseline, we detected EpCAM-positive and MCAM-positive CTCs in 12 of 68 (18%) and 8 of 68 (12%) patients, respectively. After one cycle, this was 7 of 44 (16%) and 7 of 44 (16%) patients, respectively. The detection rate improved from 18% at baseline and 16% after one cycle with EpCAM to 25% (P ¼ 0.08) and 30% (P ¼ 0.02), respectively, with EpCAM/ MCAM. No patients with MCAM-positive CTCs versus 23% of patients without MCAM-positive CTCs at baseline achieved pCR (P ¼ 0.13). EpCAM-positive CTCs and CEC counts were not correlated to pCR. Combined EpCAM/MCAM CellSearch enrichment thus increased the CTC detection rate in stage II/III pBC. We found no associations of CTC and CEC counts with pCR to NAC. The clinical relevance of MCAM-positive CTCs deserves further study.

show abstract

“…Pierga and colleagues [53] found ≥1 CTC/7.5 ml in 23% of 97 patients before administrating neoadjuvant chemotherapy (NAC) and in 17% of 86 patients after NAC. Th e detection of ≥1 CTC/7.5 ml before NAC, after NAC, or at both time points in the above study was associated with worse distant metastasis-free survival and overall survival at a median follow-up of 36 months [54]. In another study ≥1 CTC/7.5 ml were detected in 21.6% of 213 patients before NAC and in 10.6% of 207 patients after NAC [55].…”

Section: Clinical Relevance Of Ctcs (Cellsearch®)mentioning

confidence: 49%

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

2012

Recent Results in Cancer Research

View full text Add to dashboard Cite

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

Abstract: Detection of > or =1 CTC/7.5 ml before neoadjuvant chemotherapy can accurately predict OS. Our findings may change the clinical management of nonmetastatic breast cancer and indicate that the metastatic efficiency of CTC could be higher than previously reported.

Cited by 227 publications

References 10 publications

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

Contact Info

Product

Resources

About